Serum urate and lung cancer: a cohort study and Mendelian randomization using UK Biobank.

Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE

Publication: 2001- : London : BioMed Central Ltd.
Original Publication: London : Current Science Ltd., c2000-

Registries*; Lung Neoplasms/*genetics ; Mendelian Randomization Analysis/*methods ; Uric Acid/*blood; Adult ; Aged ; Biomarkers, Tumor/blood ; Female ; Follow-Up Studies ; Humans ; Incidence ; Lung Neoplasms/blood ; Lung Neoplasms/epidemiology ; Male ; Middle Aged ; Time Factors ; United Kingdom/epidemiology

Background: Serum urate is the most abundant small molecule with antioxidant properties found in blood and the epithelial lining fluid of the respiratory system. Moderately raised serum urate is associated with lower rates of lung cancer and COPD in smokers but whether these relationships reflect antioxidant properties or residual confounding is unknown.
Methods: We investigated the observational and potentially causal associations of serum urate with lung cancer incidence and FEV 1 using one-sample Mendelian randomization (MR) and the UK Biobank resource. Incident lung cancer events were identified from national cancer registries as FEV 1 was measured at baseline. Observational and genetically instrumented incidence rate ratios (IRRs) and risk differences per 10,000 person-years (PYs) by smoking status were estimated.
Results: The analysis included 359,192 participants and 1,924 lung cancer events. The associations between measured urate levels and lung cancer were broadly U-shaped but varied by sex at birth with the strongest associations in current smoking men. After adjustment for confounding variables, current smoking men with low serum urate (100 µmol/L) had the highest predicted lung cancer incidence at 125/10,000 PY (95%CI 56-170/10,000 PY) compared with 45/10,000 PY (95%CI 38-47/10,000 PY) for those with the median level (300 µmol/L). Raised measured urate was associated with a lower baseline FEV 1 . The MR results did not support a causal relationship between serum urate and lung cancer or FEV 1 .
Conclusions: We found no evidence that serum urate is a modifiable risk factor for respiratory health or lung cancer.

Thorax. 2018 Aug;73(8):748-757. (PMID: 29187594)
Free Radic Biol Med. 1993 Jun;14(6):615-31. (PMID: 8325534)
Am J Physiol. 1999 Feb;276(2):L289-96. (PMID: 9950891)
Br J Cancer. 2017 Nov 7;117(10):1572-1579. (PMID: 28898231)
Arthritis Res Ther. 2019 Jan 9;21(1):13. (PMID: 30626429)
Nat Commun. 2020 Jun 2;11(1):2767. (PMID: 32488095)
Int J Med Sci. 2011;8(6):470-8. (PMID: 21850198)
FASEB J. 1988 Dec;2(15):3092-6. (PMID: 3192041)
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034. (PMID: 28641372)
Thorax. 2014 Nov;69(11):1021-6. (PMID: 24904021)
Curr Pharm Des. 2005;11(32):4145-51. (PMID: 16375736)
Eur J Clin Invest. 1997 Jun;27(6):484-90. (PMID: 9229228)
BMJ. 2017 Jun 7;357:j2376. (PMID: 28592419)
Mol Biol Evol. 2002 May;19(5):640-53. (PMID: 11961098)
Lancet Respir Med. 2015 Oct;3(10):769-81. (PMID: 26423011)
Br J Cancer. 2018 Apr;118(8):1130-1141. (PMID: 29567982)
Proc Natl Acad Sci U S A. 1981 Nov;78(11):6858-62. (PMID: 6947260)
Int J Biochem Cell Biol. 1995 Nov;27(11):1153-9. (PMID: 7584600)
Thorax. 2020 Nov;75(11):955-964. (PMID: 32855344)
Proc Natl Acad Sci U S A. 1988 Dec;85(24):9748-52. (PMID: 3200852)
Appl Health Econ Health Policy. 2016 Aug;14(4):409-418. (PMID: 26873091)
Wellcome Open Res. 2019 Nov 26;4:186. (PMID: 32760811)
Obesity (Silver Spring). 2018 Nov;26(11):1796-1806. (PMID: 30358150)
Antioxidants (Basel). 2020 May 06;9(5):. (PMID: 32384764)
PLoS One. 2019 May 31;14(5):e0214311. (PMID: 31150407)
Ann Rheum Dis. 2018 Jul;77(7):1039-1047. (PMID: 29437585)
Respir Res. 2018 Jun 4;19(1):110. (PMID: 29866121)
Eur Respir J. 2014 Jan;43(1):43-53. (PMID: 23645404)
PLoS Med. 2015 Mar 31;12(3):e1001779. (PMID: 25826379)
Nat Genet. 2013 Feb;45(2):145-54. (PMID: 23263486)
J Mol Evol. 1992 Jan;34(1):78-84. (PMID: 1556746)

United Kingdom WT_ Wellcome Trust; MC_PC_17228 United Kingdom MRC_ Medical Research Council; MC_QA137853 United Kingdom MRC_ Medical Research Council; 209207/Z/17/Z United Kingdom WT_ Wellcome Trust

Keywords: Causal relationship; Lung cancer; Lung function; Mendelian randomization; Smoking phenotypes; Urate

0 (Biomarkers, Tumor)
268B43MJ25 (Uric Acid)

Date Created: 20210617 Date Completed: 20211206 Latest Revision: 20240402

20240402

PMC8210393

10.1186/s12931-021-01768-y

34134711